Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23316787 | 0.89 | RPS6KB1 (0.81) | RPS6KB1 | |
| SCHEMBL23316966 | 0.89 | RPS6KB1 (0.80) | RPS6KB1 | |
| SCHEMBL23316971 | 0.88 | RPS6KB1 (0.79) | RPS6KB1 | |
| SCHEMBL20445802 | 0.86 | RPS6KB1 (1.00) | RPS6KB1 | |
| SCHEMBL20445831 | 0.84 | RPS6KB1 (1.00) | RPS6KB1 | |
| SCHEMBL20593864 | 0.84 | RPS6KB1 (1.00) | RPS6KB1 | |
| SCHEMBL20593775 | 0.83 | RPS6KB1 (1.00) | RPS6KB1 | |
| SCHEMBL20445791 | 0.81 | RPS6KB1 (0.77) | RPS6KB1 | |
| SCHEMBL20445790 | 0.81 | RPS6KB1 (0.77) | RPS6KB1 | |
| SCHEMBL20445832 | 0.80 | RPS6KB1 (1.00) | RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356348-B1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3356348-B1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| US-10730882-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-04 | — | — | US | disclosed |
| US-20190292195-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2019-09-26 | — | — | US | disclosed |
| US-10344033-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292195-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | RPS6KA1, MTOR, RPTOR | RPS6KB1 6/4885 |
| US-10344033-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | RPS6KA1, MTOR, RPTOR | RPS6KB1 6/4885 |
| US-10730882-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | RPS6KA1, MTOR, RPTOR | RPS6KB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.